Archives

by in
Entry Author Date Location
Pfizer Grows in Cambridge, Repligen Eyes Imaging Approval, GI Dynamics Gets Aussie IPO, & More Boston-Area Life Sciences News 09/02/11 Boston
GI Dynamics Raises $85M USD in Aussie IPO 08/30/11 Boston
Genomatica Files for IPO, Tandem Diabetes Raises $12M, Zogenix Looks to Raise Almost $50M, & More San Diego Life Sciences News 08/25/11 San Diego
San Diego’s Tandem Diabetes Raises $12 Million While Insulin Pump Is Under Review 08/22/11 San Diego
T2 Nabs $23M, Ironwood Seeks IBS Drug Approval, FDA Sets Deadline for Alkermes Drug, & More Boston-Area Life Sciences News 08/12/11 Boston
Bydureon FDA Deadline Set 08/10/11 San Diego
Helmsley Trust Funds New Boston-Based Website for Diabetes Patients 08/10/11 Boston
Amylin & Takeda Halt Obesity Drug Development 08/04/11 San Diego
GI Dynamics and Exa File for IPOs in Weight Loss Devices, Automotive Software 08/04/11 Boston
Biogen Gets Euro Approval, BSX Shows Solid Q2, Alkermes Tries Again, & More Boston-Area Life Sciences News 07/29/11 Boston
Bydureon Sent Back to FDA 07/28/11 San Diego
Trius and Bayer Sign Deal, Brooks Buys Nexus Biosystems, Wildcat Discovery Gets $7.5M Financing, & More San Diego Life Sciences News 07/28/11 San Diego
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial Demanded by FDA 07/07/11 San Diego
Optivia Biotech Finds its Way to Profits, With a Little Help from Friends at the FDA 07/05/11 San Francisco
Amylin Buoyed by Diabetes Trials, Vital Therapies Raises $22.6M, Acutus Medical Gets Seed Cash, & More San Diego Life Sciences News 06/30/11 San Diego
Bristol Churns Out Diabetes Data 06/27/11 New York
The Auto Magnate and the Scientist: How Mass General is Working With Lee Iacocca to Find a Diabetes Cure 06/24/11 Boston
A San Diego Sampler from the War on Diabetes 06/24/11 San Diego
Link Between Cardiovascular And Metabolic Diseases? That’s What Esperion Therapeutics Founder Has Been Trying To Tell You 06/23/11 Detroit
Amylin, Alkermes Diabetes Med OKd in EU 06/21/11 San Diego
Orexigen Halts U.S. Work on Weight Loss Drug, Illumina Cuts Price for Sequencing Patient Genomes, Ambit Pulls IPO, & More San Diego Life Sciences News 06/09/11 San Diego
Amylin Gets TRO Against Lilly 05/26/11 San Diego
Shire Buys Advanced BioHealing for $750 Million 05/17/11 New York
Amylin Sues Eli Lilly, Arguing Breach of Contract in Marketing Rival Diabetes Drug 05/16/11 San Diego
Halozyme Deal Could Yield $83M, Wireless Health Leaders Converge, Readers Vote on Worst Drug Names, & More San Diego Life Sciences News 05/12/11 San Diego
Kilimanjaro Energy Seeks to Pop Loose Trillions’ Worth of Underground Oil, Save the World 05/02/11 San Francisco
CoDa Therapeutics Adds $19M Round, Led by Domain, to Pursue Diabetes Complication 04/18/11 San Diego
Biotech’s Missed Opportunity: Small-Town and Rural America 04/18/11 National
Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug 04/15/11 San Diego
Medivation Flunks Huntington’s Trial, Calibra Nabs Venture Cash, Open Source Biology Comes to SF, & More Bay Area Life Sciences News 04/15/11 San Francisco
Page 3 of 10 « previous page · next page »

Xconomy Events Across the Network

XSITE 2013: Boston’s Tech Revival

Boston · 6/19/13
9:00 am

More Xconomy Events

Xconomy’s Most Popular

  1. Don’t Panic, But We’ve Passed Peak Apple. And Google. And Facebook.
  2. With Big Bucks Chasing Big Data, Will Consumers Get a Cut?
  3. Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian
  4. 11 Reasons Why Flickr, Not Facebook, Is the Place to Put Your Photos
  5. Digital Lumens, Finding Its Identity, Brings Cost & Energy Savings to Light

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.